Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic

  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Biogen Idec (NQ: BIIB )

158.01 +2.01 (+1.29%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Biogen Idec

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
48 49 Next >
Biogen Received European Commission Approval for SKYCLARYS® (omaveloxolone), the First Therapy to Treat Friedreich’s Ataxia
From Biogen Inc.
Via GlobeNewswire
Looking At Biogen's Recent Unusual Options Activity
Via Benzinga
3 Millionaire-Maker Stocks to Buy While the Gettin’ Is Good
For patient, long-term investors, these three underestimated names can easily become millionaire-maker stocks. 
Via InvestorPlace
Here's How Much You Would Have Made Owning Biogen Stock In The Last 20 Years
Via Benzinga
7 Biotech Stocks Fighting America’s Deadliest Diseases
Although the human condition can be alarmingly frail at times, these groundbreaking biotech stocks are aiming to right the ship. 
Via InvestorPlace
Critical Insights From Biogen Analyst Ratings: What You Need To Know
Via Benzinga
$1000 Invested In This Stock 20 Years Ago Would Be Worth $6,100 Today
Via Benzinga
Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer's, Shifts Focus On Newer Medicines
Latest on Biogen's decision to discontinue Aduhelm, its Alzheimer's drug, following controversial FDA approval. 
Via Benzinga
Exposures Product Safety
Biogen to Realign Resources for Alzheimer's Disease Franchise
From Biogen Inc.
Via GlobeNewswire
NeuroSense's (NASDAQ: NRSN) ALS Drug Candidate Shows Promise In Recent Phase 2b Trial; More Milestones To Come In 2024
Amyotrophic lateral sclerosis (ALS) is a progressive neurological disease that kills the nerve cells controlling the voluntary movement of muscles. It is incurable and results in complete paralysis and... 
Via Benzinga
AT&T To Rally Around 44%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. 
Via Benzinga
Comparing Biogen With Industry Competitors In Biotechnology Industry
Via Benzinga
Understanding Biogen's Position In Biotechnology Industry Compared To Competitors
Via Benzinga
Slow Market Penetration For Biogen's Another Alzheimer's Drug: UBS Highlights Risks, Forecasts
UBS insights on Biogen Inc's challenges with Leqembi in the Alzheimer's market. Analyst downgrades, revised sales estimates, and CEO's growth strategy. 
Via Benzinga
Highlights From the 2024 JPMorgan Health Care Conference
Weight loss drugs are taking center spotlight, but other developing treatments could change how we live. 
Via The Motley Fool
These Could Be the Biggest Nasdaq-100 Winners in 2024, According to Wall Street
Nice gains could be on the way for three stocks if analysts are right. 
Via The Motley Fool
Evolving Landscape For Alzheimer's Blood Tests Gains Momentum Amid Inaccuracy Concerns
A less invasive alternative to PET scans, these tests offer quick identification for emerging treatments. Learn more about the latest advancements in Alzheimer's detection. 
Via Benzinga
Analyst Assesses Cell-Programming Focused Ginkgo Bioworks' Positioning Amid Revenue Surge, Program Adjustments
Wednesday, Ginkgo Bioworks Holdings Inc (NYSE: DNA) released preliminary FY23 sales of $250 million-$260 million, compared to the consensus of $258.65 million. 
Via Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $800 Today
Via Benzinga
Looking Into Biogen's Recent Short Interest
Via Benzinga
2 low-priced gene therapy stocks to speculate on
Gene therapy differs from gene editing, which is getting the lion's share of headlines. While gene editing is a form of gene therapy, there are basic diffe 
Via MarketBeat
Exposures Product Safety
Eli Lilly, Crispr, Biogen Lead Pharma And Biotech Stocks To Great Expectations In 2024
Between buyouts, obesity drugs and neuroscience progress, biotech stocks stand to gain. 
Via Investor's Business Daily
Wall Street Thinks These 2 Biotech Stocks Could Soar in 2024
These two biotech stocks sport notable 12-month price targets. However, they are also uber-risky. 
Via The Motley Fool
3 Biotech Stocks at the Forefront of the Quest for Eternal Youth
Biotech stocks targeting longevity could uncover the fountain of youth in coming years, offering a prime investment opportunity today. 
Via InvestorPlace
Government-granted Patent Monopolies Are Not The Free Market
Our system for developing new drugs is a disaster. While we can point to great successes, they come at enormous cost. We will spend over $600B this year on prescription and non-prescription drugs -... 
Via Talk Markets
Topics Intellectual Property
Exposures Intellectual Property
Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
Via Benzinga
Healthcare Heroes: 3 Stocks Innovating in Medicine and Wellness
Discover these innovative healthcare stocks, backed by the U.S.'s $4.3 trillion health investment, offering stability and high returns. 
Via InvestorPlace
Top 3 Healthcare Stock Picks for the New Year
Buy these healthcare stocks for 2024 trading at bargain prices before their earnings inflect higher on improving fundamentals. 
Via InvestorPlace
5 Biotech stocks tapping into unmet mental health treatment needs
Here are five biotech companies currently working on drug candidates that tap into this soaring need for life-saving mental health treatments. 
Via MarketBeat
Centralized Marketing Authorizations of Generic Versions of TECFIDERA® are Revoked by the European Commission
From Biogen Inc.
Via GlobeNewswire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
48 49 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.